Exact SciencesEXAS
EXAS
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
123% more call options, than puts
Call options by funds: $251M | Put options by funds: $112M
1% more first-time investments, than exits
New positions opened: 89 | Existing positions closed: 88
0.22% more ownership
Funds ownership: 98.49% [Q3] → 98.71% (+0.22%) [Q4]
1% less funds holding
Funds holding: 585 [Q3] → 578 (-7) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 200
17% less capital invested
Capital invested by funds: $12.4B [Q3] → $10.3B (-$2.11B) [Q4]
22% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
25%
upside
Avg. target
$62
49%
upside
High target
$73
76%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Guggenheim Subbu Nambi 15% 1-year accuracy 3 / 20 met price target | 44%upside $60 | Buy Reiterated | 11 Apr 2025 |
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 32%upside $55 | Overweight Maintained | 10 Apr 2025 |
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 44%upside $60 | Outperform Initiated | 10 Apr 2025 |
RBC Capital Gerard Cassidy 30% 1-year accuracy 11 / 37 met price target | 25%upside $52 | Sector Perform Initiated | 13 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 68%upside $70 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 7 articles about EXAS published over the past 30 days
Positive
Investors Business Daily
2 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Positive
Zacks Investment Research
4 days ago
Tap Into the Silver Economy Boom With These Aging Demographics Stocks
The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.
Neutral
Business Wire
5 days ago
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, “Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights,” affirms that the Oncotype DX test provides accurate and reliable information t.
Neutral
Business Wire
2 weeks ago
Exact Sciences Schedules First Quarter 2025 Earnings Call
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursd.
Neutral
Business Wire
2 weeks ago
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening.
Negative
Investors Business Daily
3 weeks ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
Negative
Zacks Investment Research
3 weeks ago
Should You Retain Exact Sciences Stock in Your Portfolio Now?
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
Neutral
Business Wire
1 month ago
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has received the 2025 Gallup Exceptional Workplace Award (GEWA), marking the second year in a row the company has received this prestigious recognition. This award recognizes the most engaged workplace cultures in the world. Gallup created the Exceptional Workplace Award to identify excellence and celebrate organizations that incorporate employee e.
Neutral
Business Wire
1 month ago
New Data Highlight the Positive Impact of Exact Sciences' Oncotype DX® Test on Patient Care and Healthcare Efficiency
BAAR, Switzerland--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score® test at the 19th St. Gallen International Breast Cancer Conference in Vienna, Austria. A UK study1 explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical speci.
Neutral
Zacks Investment Research
1 month ago
3 Top Cancer Biotechs to Keep An Eye On in 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Charts implemented using Lightweight Charts™